Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 505

1.

Nanoparticle Toxicity In Fish Models.

Cazenave J, Ale A, Bacchetta C, Rossi AS.

Curr Pharm Des. 2019 Sep 12. doi: 10.2174/1381612825666190912165413. [Epub ahead of print]

PMID:
31512995
2.

Exposure to a nanosilver-enabled consumer product results in similar accumulation and toxicity of silver nanoparticles in the marine mussel Mytilus galloprovincialis.

Ale A, Liberatori G, Vannuccini ML, Bergami E, Ancora S, Mariotti G, Bianchi N, Galdopórpora JM, Desimone MF, Cazenave J, Corsi I.

Aquat Toxicol. 2019 Jun;211:46-56. doi: 10.1016/j.aquatox.2019.03.018. Epub 2019 Mar 28.

PMID:
30946994
3.

Effect of Landscape Changes on Water Quality and Health Status of Heptapterus mustelinus (Siluriformes, Heptapteridae).

Vreys N, Amé MV, Filippi I, Cazenave J, Valdés ME, Bistoni MA.

Arch Environ Contam Toxicol. 2019 Apr;76(3):453-468. doi: 10.1007/s00244-018-00593-7. Epub 2019 Jan 19.

PMID:
30661090
4.

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Herbrecht R, Ojeda-Uribe M, Kientz D, Fohrer C, Bohbot A, Hinschberger O, Liu KL, Remy E, Ernst C, Lin JS, Corash L, Cazenave JP.

Vox Sang. 2018 May 21. doi: 10.1111/vox.12663. [Epub ahead of print]

PMID:
29786866
5.

Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation.

Ohlmann P, Hechler B, Chafey P, Ravanat C, Isola H, Wiesel ML, Cazenave JP, Gachet C.

Transfusion. 2016 Sep;56(9):2239-47. doi: 10.1111/trf.13670. Epub 2016 Jun 1.

PMID:
27250038
6.

Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation.

Cinqualbre J, Kientz D, Remy E, Huang N, Corash L, Cazenave JP.

Transfusion. 2015 Jul;55(7):1710-20. doi: 10.1111/trf.13100. Epub 2015 Apr 9.

PMID:
25857325
7.

Dehydration of blood platelets by zeodration: in vitro characterization and hemostatic properties in vivo.

Donnet T, Ravanat C, Eckly A, Maurer E, Alame G, Ziessel C, Mangin PH, Freund M, Cazenave JP, Gachet C, Rendu F.

Transfusion. 2015 Sep;55(9):2207-18. doi: 10.1111/trf.13121. Epub 2015 Apr 9.

PMID:
25856501
8.

Physiological and biochemical responses of Eichhornia crassipes exposed to Cr (III).

González CI, Maine MA, Cazenave J, Sanchez GC, Benavides MP.

Environ Sci Pollut Res Int. 2015 Mar;22(5):3739-47. doi: 10.1007/s11356-014-3558-4. Epub 2014 Sep 30.

PMID:
25263412
9.

[Blood platelets: conclusion].

Cazenave JP.

Bull Acad Natl Med. 2013 Feb;197(2):419-23. French. No abstract available.

PMID:
24919371
10.

[Ethics and transfusion--seminar report].

Hervé C, Tissot JD, Bouësseau MC, Pottier R, Monsellier M, Garraud O, Hermine O, Sannié T, Cazenave JP, Cabaud JJ, Lefrère JJ.

Transfus Clin Biol. 2014 May;21(2):66-76. doi: 10.1016/j.tracli.2014.03.001. Epub 2014 May 6. French.

PMID:
24814818
11.

Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care.

Lieberman L, Devine DV, Reesink HW, Panzer S, Wong J, Raison T, Benson S, Pink J, Leitner GC, Horvath M, Compernolle V, Prado Scuracchio PS, Wendel S, Delage G, Nahirniak S, Dongfu X, Krusius T, Juvonen E, Sainio S, Cazenave JP, Guntz P, Kientz D, Andreu G, Morel P, Seifried E, Hourfar K, Lin CK, O'Riordan J, Raspollini E, Villa S, Rebulla P, Flanagan P, Teo D, Lam S, Ang AL, Lozano M, Sauleda S, Cid J, Pereira A, Ekermo B, Niederhauser C, Waldvogel S, Fontana S, Desborough MJ, Pawson R, Li M, Kamel H, Busch M, Qu L, Triulzi D.

Vox Sang. 2014 Oct;107(3):276-311. doi: 10.1111/vox.12103. Epub 2014 May 7. No abstract available.

PMID:
24801438
12.

Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.

Prudent M, D'Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher A, Lion N, Schubert P, Steil L, Thiele T, Tissot JD, Völker U, Zolla L.

Transfus Med Rev. 2014 Apr;28(2):72-83. doi: 10.1016/j.tmrv.2014.02.002. Epub 2014 Feb 25. Review.

PMID:
24685438
13.

Bacterial contamination in platelet concentrates.

Pietersz RN, Reesink HW, Panzer S, Oknaian S, Kuperman S, Gabriel C, Rapaille A, Lambermont M, Deneys V, Sondag D, Ramírez-Arcos S, Goldman M, Delage G, Bernier F, Germain M, Vuk T, Georgsen J, Morel P, Naegelen C, Bardiaux L, Cazenave JP, Dreier J, Vollmer T, Knabbe C, Seifried E, Hourfar K, Lin CK, Spreafico M, Raffaele L, Berzuini A, Prati D, Satake M, de Korte D, van der Meer PF, Kerkhoffs JL, Blanco L, Kjeldsen-Kragh J, Svard-Nilsson AM, McDonald CP, Symonds I, Moule R, Brailsford S, Yomtovian R, Jacobs MR.

Vox Sang. 2014 Apr;106(3):256-83. doi: 10.1111/vox.12098. Review. No abstract available.

PMID:
24654780
14.

Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.

Hechler B, Ohlmann P, Chafey P, Ravanat C, Eckly A, Maurer E, Mangin P, Isola H, Cazenave JP, Gachet C.

Transfusion. 2013 Jun;53(6):1187-200. doi: 10.1111/j.1537-2995.2012.03923.x. Epub 2012 Oct 15.

PMID:
23067365
15.

HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule.

Lenormand C, Bausinger H, Gross F, Signorino-Gelo F, Koch S, Peressin M, Fricker D, Cazenave JP, Bieber T, Hanau D, de la Salle H, Tourne S.

J Immunol. 2012 Apr 15;188(8):3903-11. doi: 10.4049/jimmunol.1103048. Epub 2012 Mar 9.

16.

Characterization of megakaryocyte development in the native bone marrow environment.

Eckly A, Strassel C, Cazenave JP, Lanza F, Léon C, Gachet C.

Methods Mol Biol. 2012;788:175-92. doi: 10.1007/978-1-61779-307-3_13.

PMID:
22130708
17.

Evaluation of soluble glycoprotein V as a marker of venous thromboembolism.

Gayol S, Kirchgesner T, Kopferschmitt J, Meyer N, Sauleau E, Wiesel ML, Cazenave JP, Gachet C, Lanza F.

Thromb Haemost. 2012 Jan;107(1):184-7. doi: 10.1160/TH11-09-0630. Epub 2011 Nov 24. No abstract available.

PMID:
22116210
18.

[Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].

Cazenave JP.

Bull Acad Natl Med. 2010 Dec;194(9):1707-19; discussion 1719-20. Review. French.

PMID:
22043595
19.

Hirudin and heparin enable efficient megakaryocyte differentiation of mouse bone marrow progenitors.

Strassel C, Eckly A, Léon C, Moog S, Cazenave JP, Gachet C, Lanza F.

Exp Cell Res. 2012 Jan 1;318(1):25-32. doi: 10.1016/j.yexcr.2011.10.003. Epub 2011 Oct 8.

PMID:
22008103
20.

Histopathological changes in the gills and liver of Prochilodus lineatus from the Salado River basin (Santa Fe, Argentina).

Troncoso IC, Cazenave J, Bacchetta C, Bistoni Mde L.

Fish Physiol Biochem. 2012 Jun;38(3):693-702. doi: 10.1007/s10695-011-9551-7. Epub 2011 Aug 18.

PMID:
21850399
21.

[Pathogen inactivation technologies: a complex but necessary debate].

Andreu G, Cazenave JP, Garraud O, Lefrère JJ.

Transfus Clin Biol. 2011 Aug;18(4):443. doi: 10.1016/j.tracli.2011.04.001. Epub 2011 Jul 23. French. No abstract available.

PMID:
21783399
22.

[Pathogen inactivation in platelet concentrates: the French experience].

Cazenave JP.

Transfus Clin Biol. 2011 Aug;18(4):478-84. doi: 10.1016/j.tracli.2011.05.002. Epub 2011 Jun 29. French.

PMID:
21719338
23.

Major contribution of the P2Y₁receptor in purinergic regulation of TNFα-induced vascular inflammation.

Zerr M, Hechler B, Freund M, Magnenat S, Lanois I, Cazenave JP, Léon C, Gachet C.

Circulation. 2011 May 31;123(21):2404-13. doi: 10.1161/CIRCULATIONAHA.110.002139. Epub 2011 May 16.

PMID:
21576651
24.

The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.

Hechler B, Freund M, Alame G, Leguay C, Gaertner S, Cazenave JP, Petitou M, Gachet C.

J Pharmacol Exp Ther. 2011 Aug;338(2):412-20. doi: 10.1124/jpet.111.181321. Epub 2011 Apr 28.

PMID:
21527535
25.

Increased flexibility and liposome-binding capacity of CD1e at endosomal pH.

Bushmarina N, Tourne S, Giacometti G, Signorino-Gelo F, Garcia-Alles LF, Cazenave JP, Hanau D, de la Salle H.

FEBS J. 2011 Jun;278(12):2022-33. doi: 10.1111/j.1742-4658.2011.08118.x. Epub 2011 May 13.

26.

[Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].

Cazenave JP.

Transfus Clin Biol. 2011 Apr;18(2):53-61. doi: 10.1016/j.tracli.2011.02.023. Epub 2011 Apr 6. Review. French.

PMID:
21474358
27.

Mechanisms underlying FeCl3-induced arterial thrombosis.

Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, Mangin PH, Gachet C.

J Thromb Haemost. 2011 Apr;9(4):779-89. doi: 10.1111/j.1538-7836.2011.04218.x.

28.

Biochemical stress responses in tissues of the cichlid fish Cichlasoma dimerus exposed to a commercial formulation of endosulfan.

Bacchetta C, Cazenave J, Parma MJ, Biancucci GF.

Arch Environ Contam Toxicol. 2011 Oct;61(3):453-60. doi: 10.1007/s00244-010-9635-x. Epub 2011 Jan 8.

PMID:
21221961
29.

[Occurrence of severe, persistent thrombocytopenia following allogeneic bone marrow transplantation, attributable to anti-HPA-1 allo-immunisation of the host].

Parissiadis A, Bilger K, Laplace A, Berceanu A, Schwebel M, Froelich N, Cazenave JP, Hanau D, Tourne S, Lioure B.

Transfus Clin Biol. 2010 Oct;17(4):265-8. doi: 10.1016/j.tracli.2010.07.002. Epub 2010 Oct 18. French.

PMID:
20961787
30.

Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label.

Isola H, Brandner D, Cazenave JP, Stahl E, Corash L.

Vox Sang. 2010 Nov;99(4):402. doi: 10.1111/j.1423-0410.2010.01372.x. No abstract available.

PMID:
20946313
31.

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.

Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforêt M, Raidot JP, Kandel G, Wiesel ML, Corash L.

Transfusion. 2011 Mar;51(3):622-9. doi: 10.1111/j.1537-2995.2010.02873.x. Epub 2010 Sep 16.

PMID:
20849406
32.

Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.

Eckly A, Rinckel JY, Laeuffer P, Cazenave JP, Lanza F, Gachet C, Léon C.

J Thromb Haemost. 2010 Oct;8(10):2243-51. doi: 10.1111/j.1538-7836.2010.04009.x.

33.

Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates.

Maître B, Mangin PH, Eckly A, Heim V, Cazenave JP, Lanza F, Hanau D, Gachet C.

J Thromb Haemost. 2010 Oct;8(10):2262-72. doi: 10.1111/j.1538-7836.2010.03983.x.

34.

Inventory management.

Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PA, Wong JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W, Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D, Delage G, Sarappa C, Charbonneau, Fu Y, Sarlija D, Vuk T, Strauss Patko M, Balija M, Jukić I, Ali A, Auvinen MK, Jaakonsalo E, Cazenave JP, Waller C, Kientz D, David B, Walther-Wenke G, Heiden M, Lin CK, Tsoi WC, Lee CK, Barotine-Toth K, Sawant RB, Murphy W, Quirke B, Bowler P, Shinar E, Yahalom V, Aprili G, Piccoli P, Gandini G, Tadokaro K, Nadarajan VS, de Kort W, Jansen N, Flanagan P, Forsberg PO, Hervig T, Letowska M, Lachert E, Dudziak K, Antoniewicz-Papis J, de Olim G, Nascimento F, Hindawi S, Teo D, Reddy R, Scholtz J, Swanevelder R, Rovira LP, Sauleda S, Carasa MA, Vaquero MP, Ania MA, Gulliksson H, Holdsworth S, Cotton S, Howell C, Baldwin C, Cusick RM, Geele GA, Paden C, McEvoy P, Gottschall JL, McLaughlin LS, Benjamin RJ, Eder A, Draper NL, AuBuchon JP, León de González G.

Vox Sang. 2010 Apr;98(3 Pt 1):e295-363.

PMID:
20432515
35.

Pathogen inactivation of platelet concentrates.

Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasonglès P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Almazán C, MacLennan S, Cardigan R, Franklin IM, Prowse C.

Vox Sang. 2010 Jul 1;99(1):85-95. doi: 10.1111/j.1423-0410.2010.01319.x. Epub 2010 Mar 10. No abstract available.

PMID:
20230599
36.

An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.

Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC.

Transfusion. 2010 Jun;50(6):1210-9. doi: 10.1111/j.1537-2995.2009.02579.x. Epub 2010 Jan 22.

PMID:
20113450
37.

Feasibility study of a screening assay that identifies the abnormal prion protein PrPTSE in plasma: initial results with 20,000 samples.

Guntz P, Walter C, Schosseler P, Morel P, Coste J, Cazenave JP.

Transfusion. 2010 May;50(5):989-95. doi: 10.1111/j.1537-2995.2009.02569.x. Epub 2010 Jan 15.

PMID:
20088835
38.

Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization.

Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, Gachet C.

J Thromb Haemost. 2010 Jan;8(1):173-84. doi: 10.1111/j.1538-7836.2009.03666.x. Epub 2009 Oct 24.

39.

The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site.

David T, Strassel C, Eckly A, Cazenave JP, Gachet C, Lanza F.

J Thromb Haemost. 2010 May;8(5):1077-87. doi: 10.1111/j.1538-7836.2009.03590.x. Epub 2009 Aug 19.

40.

CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.

Aleil B, Léon C, Cazenave JP, Gachet C.

J Thromb Haemost. 2009 Oct;7(10):1747-9. doi: 10.1111/j.1538-7836.2009.03554.x. Epub 2009 Jul 17. No abstract available.

41.

Multiple biomarkers responses in Prochilodus lineatus allowed assessing changes in the water quality of Salado River basin (Santa Fe, Argentina).

Cazenave J, Bacchetta C, Parma MJ, Scarabotti PA, Wunderlin DA.

Environ Pollut. 2009 Nov;157(11):3025-33. doi: 10.1016/j.envpol.2009.05.055. Epub 2009 Jul 8.

PMID:
19589632
42.

Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy.

Kessler L, Parissiadis A, Bayle F, Moreau F, Pinget M, Froelich N, Cazenave JP, Berney T, Benhamou PY, Hanau D; GRAGIL Study Group.

Am J Transplant. 2009 Aug;9(8):1961-6. doi: 10.1111/j.1600-6143.2009.02711.x. Epub 2009 Jun 12.

43.

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C.

JACC Cardiovasc Interv. 2008 Dec;1(6):631-8. doi: 10.1016/j.jcin.2008.09.004.

44.

[Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP].

Naegelen C, Isola H, Dernis D, Maurel JP, Tardivel R, Bois S, Vignoli C, Cazenave JP.

Transfus Clin Biol. 2009 May;16(2):179-89. doi: 10.1016/j.tracli.2009.03.022. Epub 2009 May 13. French.

PMID:
19443252
45.

Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome.

Strassel C, Eckly A, Léon C, Petitjean C, Freund M, Cazenave JP, Gachet C, Lanza F.

Haematologica. 2009 Jun;94(6):800-10. doi: 10.3324/haematol.2008.001032. Epub 2009 Apr 18.

46.

Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.

Rasonglès P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP.

Transfusion. 2009 Jun;49(6):1083-91. doi: 10.1111/j.1537-2995.2009.02111.x. Epub 2009 Feb 27.

PMID:
19309473
47.

The assembly of CD1e is controlled by an N-terminal propeptide which is processed in endosomal compartments.

Maître B, Angénieux C, Wurtz V, Layre E, Gilleron M, Collmann A, Mariotti S, Mori L, Fricker D, Cazenave JP, van Dorsselaer A, Gachet C, de Libero G, Puzo G, Hanau D, de la Salle H.

Biochem J. 2009 May 1;419(3):661-8. doi: 10.1042/BJ20082204.

48.

Use of tandem Biacore-mass spectrometry to identify platelet membrane targets of novel monoclonal antibodies.

Ravanat C, Wurtz V, Ohlmann P, Fichter M, Cazenave JP, Vandorsselaer A, Lanza F, Gachet C.

Anal Biochem. 2009 Mar 15;386(2):237-43. doi: 10.1016/j.ab.2008.12.010. Epub 2008 Dec 24.

PMID:
19135971
49.

Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.

Eckly A, Strassel C, Freund M, Cazenave JP, Lanza F, Gachet C, Léon C.

Blood. 2009 Apr 2;113(14):3182-9. doi: 10.1182/blood-2008-06-164061. Epub 2008 Nov 4.

PMID:
18984861
50.

Plasma levels of soluble platelet glycoprotein V are linked to fasting blood glucose in patients with type 2 diabetes.

Aleil B, Kessler L, Meyer N, Wiesel ML, Simeoni J, Cazenave JP, Pinget M, Gachet C, Lanza F.

Thromb Haemost. 2008 Oct;100(4):713-5. No abstract available.

PMID:
18841299

Supplemental Content

Loading ...
Support Center